作者: Taturo Udagawa , Henk M. W. Verheul , Robert J. D’Amato
DOI: 10.1007/978-1-59259-453-5_16
关键词: Medicine 、 Sedative 、 Thalidomide 、 Lepromatous leprosy 、 Vascular endothelial growth factor 、 Pharmacology 、 Teratology 、 Corneal neovascularization 、 Fetal limb
摘要: Thalidomide was developed in 1958 by Chemie Grunenthal as an oral sedative. Subsequently, McBride (1) and Lenz (2) described the association between maternal usage of thalidomide fetal limb defects. The effect a teratogen experimentally confirmed number species (3–8). By time withdrawn from market 1962, thousands babies worldwide were estimated to have been born with thalidomide-related As consequence, mechanism which causes birth defects has intensively investigated. Nevertheless, remained elusive (9).